Sangamo Therapeutics, Inc. (NASDAQ:SGMO) management will conduct a conference call for 4th November 2020 at 5:00 PM Eastern Time to discuss financial results and companys performance for 3Q20.
The conference call will also be available live on the website www.sangamo.com
Earnings Expectation
Sangamo Therapeutics, Inc. is reporting third quarter financial results on Wednesday 4th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SGMO is expected to report 3Q20 loss of $ 0.24 per share from revenue of $ 26.55 million.
For the full year, analysts anticipate top line of $ 89.47 million, while looking forward to loss of $ 1.12 per share bottom line.
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The companys zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
